{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:42:11Z","timestamp":1783489331846,"version":"3.55.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Cardiovascular disease (CVD) has emerged as the leading cause of death from prostate cancer (PCa) in recent decades, bringing a great disease burden worldwide. Men with preexisting CVD have an increased risk for major adverse cardiovascular events when treated with androgen deprivation therapy (ADT). The present study aimed to explore the prevalence and risk evaluation of CVD among people with newly diagnosed PCa in China.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Clinical data of newly diagnosed PCa patients were retrospectively collected from 34 centers in China from 2010 to 2022 through convenience sampling. CVD was defined as myocardial infarction, arrhythmia, heart failure, stroke, ischemic heart disease, and others. CVD risk was estimated by calculating Framingham risk scores (FRS). Patients were accordingly divided into low-, medium-, and high-risk groups. <jats:italic toggle=\"yes\">\u03c7<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup> or Fisher\u2019s exact test was used for comparison of categorical variables.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 4253 patients were enrolled in the present study. A total of 27.0% (1147\/4253) of patients had comorbid PCa and CVD, and 7.2% (307\/4253) had two or more CVDs. The enrolled population was distributed in six regions of China, and approximately 71.0% (3019\/4253) of patients lived in urban areas. With imaging and pathological evaluation, most PCa patients were diagnosed at an advanced stage, with 20.5% (871\/4253) locally progressing and 20.5% (871\/4253) showing metastasis. Most of them initiated prostatectomy (46.6%, 1983\/4253) or regimens involving ADT therapy (45.7%, 1944\/4253) for prostate cancer. In the present PCa cohort, 43.1% (1832\/4253) of patients had hypertension, and half of them had poorly controlled blood pressure. With FRS stratification, as expected, a higher risk of CVD was related to aging and metabolic disturbance. However, we also found that patients with treatment involving ADT presented an originally higher risk of CVD than those without ADT. This was in accordance with clinical practice, i.e., aged patients or patients at advanced oncological stages were inclined to accept systematic integrative therapy instead of surgery. Among patients who underwent medical castration, only 4.0% (45\/1118) received gonadotropin releasing hormone antagonists, in stark contrast to the grim situation of CVD prevalence and risk.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>PCa patients in China are diagnosed at an advanced stage. A heavy CVD burden was present at the initiation of treatment. Patients who accepted ADT-related therapy showed an original higher risk of CVD, but the awareness of cardiovascular protection was far from sufficient.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003087","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T08:00:08Z","timestamp":1712995208000},"page":"1324-1331","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Prevalence and risk evaluation of cardiovascular disease in the newly diagnosed prostate cancer population in China: A nationwide, multi-center, population-based cross-sectional study"],"prefix":"10.1097","volume":"137","author":[{"given":"Weiyu","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Urology, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Biostatistics, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, Beijing Hospital, National Center of Gerontology, Beijing 100005, China"},{"name":"Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Ying","sequence":"additional","affiliation":[{"name":"Department of Urology, Wuhan Union Hospital, Huazhong University of Science & Technology, Wuhan, Hubei 430022, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renbin","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Urology, The Third People\u2019s Hospital of Chengdu, Chengdu, Sichuan 610014, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Urology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenting","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urologic Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujun","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Urology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"},{"name":"National Cancer Center, Beijing 100021, China"},{"name":"National Clinical Research Center for Cancer, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhannan","family":"Si","sequence":"additional","affiliation":[{"name":"Department of Urology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China"},{"name":"National Cancer Center, Beijing 100021, China"},{"name":"National Clinical Research Center for Cancer, Beijing 100021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Urology, Liaoning Cancer Hospital, Shenyang, Liaoning 110801, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeng","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300141, China"},{"name":"Tianjin Institute of Urology, Tianjin Medical University, Tianjin 300141, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, Lu\u2019an Affiliated Hospital of Anhui Medical University, Lu\u2019an, Anhui 237322, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Harbin Medical University Affiliated Cancer Hospital, Harbin, Heilongjiang 150081, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116023, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhitao","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Urology Surgery, Fujian Cancer Hospital, Fuzhou, Fujian 350014, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Urology Surgery, Hunan Cancer Hospital, Changsha, Hunan 410031, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhi","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Urology Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"key":"R1-20250602","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: Profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J"},{"key":"R2-20250602","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s44197-023-00103-6","article-title":"Global Burden of Prostate Cancer and Association with socioeconomic status, 1990-2019: A systematic analysis from the Global Burden of Disease Study","volume":"13","author":"Zhang","year":"2023","journal-title":"J Epidemiol Glob Health"},{"key":"R3-20250602","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: Treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"key":"R4-20250602","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur Urol"},{"key":"R5-20250602","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11864-021-00846-z","article-title":"Cardiovascular toxicities of androgen deprivation therapy","volume":"22","author":"Challa","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"R6-20250602","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"R7-20250602","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","article-title":"Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer","volume":"133","author":"Bhatia","year":"2016","journal-title":"Circulation"},{"key":"R8-20250602","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1097\/JU.0000000000000384","article-title":"Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease","volume":"202","author":"Margel","year":"2019","journal-title":"J Urol"},{"key":"R9-20250602","doi-asserted-by":"crossref","first-page":"215927","DOI":"10.1016\/j.canlet.2022.215927","article-title":"Prostate cancer treatment \u2013 China\u2019s perspective","volume":"550","author":"Liu","year":"2022","journal-title":"Cancer Lett"},{"key":"R10-20250602","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: The Framingham Heart Study","volume":"117","author":"D\u2019Agostino","year":"2008","journal-title":"Circulation"},{"key":"R11-20250602","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1200\/JCO.2010.31.2330","article-title":"Impact of comorbidity on survival among men with localized prostate cancer","volume":"29","author":"Albertsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"R12-20250602","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1161\/CIR.0000000000000395","article-title":"The heart of 25 by 25: Achieving the goal of reducing global and regional premature deaths from cardiovascular diseases and stroke: A modeling study from the American Heart Association and World Heart Federation","volume":"133","author":"Sacco","year":"2016","journal-title":"Circulation"},{"key":"R13-20250602","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0140-6736(15)00551-6","article-title":"Cause-specific mortality for 240 causes in China during 1990-2013: A systematic subnational analysis for the Global Burden of Disease Study 2013","volume":"387","author":"Zhou","year":"2016","journal-title":"Lancet"},{"key":"R14-20250602","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"key":"R15-20250602","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.euf.2019.11.005","article-title":"Variation in the prescription of androgen deprivation therapy in intermediate- and high-risk prostate cancer patients treated with radiotherapy in the Netherlands, and Adherence to European Association of Urology Guidelines: A population-based study","volume":"7","author":"Rijksen","year":"2021","journal-title":"Eur Urol Focus"},{"key":"R16-20250602","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/JU.0000000000002340","article-title":"Comparison of surgical or medical castration-related cardiotoxicity in patients with prostate cancer","volume":"207","author":"Kan","year":"2022","journal-title":"J Urol"},{"key":"R17-20250602","doi-asserted-by":"crossref","first-page":"820403","DOI":"10.1155\/2015\/820403","article-title":"The prevalence of cardiac risk factors in men with localized prostate cancer undergoing androgen deprivation therapy in British Columbia, Canada","volume":"2015","author":"Davis","year":"2015","journal-title":"J Oncol"},{"key":"R18-20250602","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.clgc.2014.12.003","article-title":"Cardiovascular mortality in patients with metastatic prostate cancer exposed to androgen deprivation therapy: A population-based study","volume":"13","author":"Gandaglia","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"R19-20250602","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/JU.0000000000000714","article-title":"Cardiovascular risk in men with prostate cancer: Insights from the RADICAL PC study","volume":"203","author":"Leong","year":"2020","journal-title":"J Urol"},{"key":"R20-20250602","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.117.032380","article-title":"Status of hypertension in China: Results from the China hypertension survey, 2012-2015","volume":"137","author":"Wang","year":"2018","journal-title":"Circulation"},{"key":"R21-20250602","doi-asserted-by":"crossref","first-page":"e071952","DOI":"10.1136\/bmj-2022-071952","article-title":"Prevalence, awareness, treatment, and control of hypertension in China, 2004-18: Findings from six rounds of a national survey","volume":"380","author":"Zhang","year":"2023","journal-title":"BMJ"},{"key":"R22-20250602","doi-asserted-by":"crossref","first-page":"215927","DOI":"10.1016\/j.canlet.2022.215927","article-title":"Prostate cancer treatment \u2013 China\u2019s perspective","volume":"550","author":"Liu","year":"2022","journal-title":"Cancer Lett"},{"key":"R23-20250602","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1200\/JCO.22.00883","article-title":"Should prostate cancer patients with history of cardiovascular events be preferentially treated with luteinizing hormone-releasing hormone antagonists?","volume":"40","author":"Tisseverasinghe","year":"2022","journal-title":"J Clin Oncol"},{"key":"R24-20250602","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/ijc.34557","article-title":"Long-term prognostic impact of cardiovascular comorbidities in patients with prostate cancer receiving androgen deprivation therapy: A population-based competing risk analysis","volume":"153","author":"Chan","year":"2023","journal-title":"Int J Cancer"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003087","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T19:04:00Z","timestamp":1748891040000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003087","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,12]]},"assertion":[{"value":"2024-01-30","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}